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Kolberg and colleagues have recently 
published a series of papers[1-3], which for 
the first time give some idea of outcomes of 
TARGIT IORT as a tumour bed boost 
during lumpectomy after neo-adjuvant 
chemotherapy. The last of these series is 
published in the current issue of Breast 
Care. We would like to discuss these from 
two perspectives – neoadjuvant 
chemotherapy and TARGIT IORT.  
	
Neoadjuvant chemotherapy  
 
The generally accepted aims of neoadjuvant 
chemotherapy are to downsize an 
inoperable cancer, and to assess tumour 
response, particularly within ‘window-of-
opportunity’ translational research clinical 
trials.  
 
Whether it is better to give systemic therapy 
before or after surgery has been assessed in 
two large meta-analyses of randomised 
trials of neo-adjuvant vs adjuvant 
chemotherapy. In these meta-analyses, no 
difference in survival was found. However, 
they found a higher risk of loco-regional 
recurrence in patients randomised to receive 
neo-adjuvant chemotherapy before surgery 
when compared with adjuvant 
chemotherapy after surgery. The absolute 
increase in the risk of local recurrence was 
3 to 5% at 5 years. The magnitude of the 
increased recurrence risk appears to be less 
with larger surgical excision after neo-
adjuvant chemotherapy and it appears to be 
much higher when an operation is omitted 
altogether. The benefit of a smaller 
operation therefore should be balanced with 
the increased risk of local recurrence: at 5 
years, about 3% absolute increase of local 
recurrence vis a vis a 6% increased chance 
of avoiding a mastectomy[4 5]. Early Breast 
Cancer Trialists group have performed a 
new meta-analysis with individual patient 
data from over 4500 patients and these data 
have been presented but not published. 
They appear to reinforce the findings of the 
previous two meta-analyses.  
 
Therefore, if any of the benefits of NACT 
are to be realised, particularly the aim to 
convert a necessary mastectomy to breast 
conservation, an additional treatment to 
improve local control would be welcome. If 
such an intervention has systemic benefits it 
would be an additional bonus. 
	
Systemic	effect	of	TARGIT	IORT	
	
In the TARGIT-A trial[6-8], 3451 patients 
eligible for breast conserving surgery for 
breast cancer were randomly allocated to 
receive either risk-adapted TARGIT IORT 
or whole breast external beam radiotherapy 
(EBRT). TARGIT-IORT arm was found to 
be non-inferior to EBRT in terms of local 
control. In the analysis of deaths, there was 
no difference in breast cancer mortality, 
which was low in both arms of the trial. 
However, the trialists found a significantly 
lower non-breast cancer mortality for the 
TARGIT IORT patients (HR. 0.47; p = 
0.0086) (Figure 1). The irradiation of the 
lung, oesophagus and heart during 
tangential field radiation of the breast has 
been repeatedly shown to cause fatal 
cancers[9 10] and deaths due to ischemic 
heart disease[11 12]. One would expect that 
TARGIT IORT should avoid such deaths. 
This view has been vindicated by a meta-
analysis of randomised trials[13] of targeted 
radiotherapy/ partial breast irradiation) vs. 
whole external beam radiotherapy (EBRT). 
In this meta-analysis of over 4500 patients 
found that in the breast cancer populations 
where the breast cancer mortality is low 
(about 5%), the deleterious effect of whole 
breast radiation is unmasked and 
demonstrates an increased overall mortality 
– thus using targeted radiation rather than 
whole breast radiation in such patients leads 
to an improvement in overall survival albeit 
by a small absolute amount (Figure 2).  
		
	
	
Fig.	1.		Kaplan-Meier	plot	for	deaths	from	causes	other	than	breast	cancer	(17	vs	35)		in	the	randomised	TARGIT-A	trial,	showing	a	significantly	
higher	risk	of	non-breast-cancer	mortality	with	whole	breast	fractionated	radiation	given	postoperatively	over	several	weeks	(EBRT),	
compared	with	a	risk-adapted	single	dose	radiation	delivered	to	the	tumour	bed	during	the	lumpectomy	operation	(TARGIT)6-8		
	
	
	
	
	
Fig.	2.		Forest	plots	representing	meta-analysis	of	difference	in	mortality	between	partial-breast	irradiation	(PBI)	and	whole-breast	irradiation	
(WBI)	with	a	random-effects	model14.	The	trials	included	for	non-breast	cancer	(Non-BC)	mortality	were	the	Budapest	trial,	TARGIT-A,	ELIOT,	
IMRT,	and	GEC-ESTRO.	The	median	follow-up	of	all	these	trials	was	5	to	6	years.	Data	from	only	the	initial	1222	patients	in	the	TARGIT-A	trial,	
whose	median	follow-up	was	5	years,	were	included.	The	Budapest	trial	was	not	included	in	the	analysis	of	breast	cancer	(BC)	deaths	or	total	
deaths	because	these	figures	were	not	available.		
	 	
		
An interesting sub-group analysis 
performed in the TARGIT-A trial[14] was 
for survival from causes other than breast 
cancer, comparing TARGIT followed by 
EBRT vs EBRT alone (Figure 3a). The 
group that were randomised to TARGIT but 
also received EBRT had a worse prognosis 
breast cancer (as defined by the protocol) 
but would not be expected to be different 
than the rest of the cohort in terms of other 
co-morbidity; as both groups received 
EBRT, any difference found in non-breast-
cancer mortality could be attributable to the 
delivery of TARGIT IORT during 
lumpectomy.  
 
Remarkably, there were no deaths from 
non-breast cancer causes in the 
TARGIT+EBRT group compared with 24 
in the EBRT group 0/218 vs. 24/892, log-
rank p=0.012. Although the numbers are 
small and the compared groups are not the 
randomised cohorts, these data suggest that 
avoidance of EBRT toxicity may not be the 
only reason for the fewer non-breast cancer 
deaths with TARGIT IORT, and the 
difference in mortality may also be 
attributable due to a beneficial systemic 
effect of TARGIT-IORT. It leads to the 
hypothesis that the local effect of TARGIT 
on the tumor bed by inhibiting the cancer-
stimulating cytokines, may spill over to 
reduce inflammatory response to trauma 
and have significant long-term systemic 
beneficial effects, that might be protective 
against cardiac and cancer mortality[15]. 
	
	
	
Fig.	3.		Non-randomised	comparison	between	those	who	received	TARGIT	+	EBRT	and	those	who	received	EBRT	for	deaths	from	non-breast-
cancer	causes:	(above)	schema	of	the	analysed	cohorts	of	patients;	and	(below)	Kaplan–Meier	plot	depicting	deaths	from	causes	other	than	
breast	cancer	in	prepathology	patients	who	received	EBRT	–	non-randomised	comparison8,14-15.	
		
Testing of this hypothesis within a randomised trial will occur in the TARGIT-B trial. In this 
trial, patients who are younger than 45 or at high-risk of relapse, including those rendered 
suitable for breast conservation by pre-operative administration of neoadjuvant chemotherapy, 
are randomly allocated to receive a tumour bed boost either by TARGIT IORT during 
lumpectomy or by the traditional external beam radiotherapy. While an improvement in local 
control is the primary aim the specified second aim of this trial is to assess whether a TARGIT 
IORT boost has any effect on breast cancer and non-breast cancer survival.  
	
Neoadjuvant	chemotherapy	+	Surgery	including	TARGIT	IORT	
	
Kolberg and colleagues have reported the results of consecutive patients receiving TARGIT-
IORT during lumpectomy after NACT. As a comparator control, they used consecutive patients 
treated in the previous year without TARGIT-IORT, and have taken efforts to ensure that the 
two groups are matched in all other aspects in this non-randomised study. To ensure that the 
follow up period is similar, they have truncated the follow up for the historically older cohort. 
  
In their first of the three papers they reported that patients having oncoplastic breast conserving 
surgery after neo-adjuvant chemotherapy along with intraoperative TARGIT-IORT Boost, 
experienced similar local control, but statistically significantly better survival outcomes than 
those who received a postoperative EBRT boost (overall survival 96.7% vs. 81.7%, hazard ratio 
0.19, log rank p = 0.016, and distant-disease free survival 95.1% vs. 69.0, HR 0.23, log rank p = 
0.012)[2]. In the two subsequent papers, they tried to ascertain if there is any impact of tumour 
biology on this effect – by analysing the data in three different subgroups -  ER+ PgR+ Her2 
neg, Her2 positive, and triple negative tumours. The results were numerically similar, but did 
not reach statistical significance, most likely due to paucity of events; it is arguable that such an 
analysis of impact of tumour factors should normally be performed using a Cox proportional 
hazard model.  
 
While these non-randomised data are not enough to prompt a change in practice, they are 
reassuring that despite the short physical range of radiation field of TARGIT IORT, its 
effectiveness is at least as good as an externally delivered tumour bed boost and it may have a 
bonus of systemic beneficial effects. Therefore, at the very least these data give a strong support 
to clinicians and patients to participate in the TARGIT-B trial.  
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